Sage shrugs off potential competition in postpartum depression, asserts plan to remain independent
Postpartum depression (PPD), a so-far untapped market, is large enough for multiple players with 1 in 7 women diagnosed with the condition that has no specific therapies approved by the FDA. But Sage $SAGE, which reported impressive late-stage data on its pill in severe PPD patients on Monday, is not worried about potential competition.
Analysts have drawn cautious comparisons with Marinus $MRNS, whose drug ganaxolone is also under evaluation for PPD. An IV formulation of ganaxolone is currently in a Phase II study in severe PPD patients, while mid-stage data from an oral formulation of ganaxolone in moderate PPD patients is expected in the first half of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.